JP2022512672A5 - - Google Patents
Info
- Publication number
- JP2022512672A5 JP2022512672A5 JP2021519849A JP2021519849A JP2022512672A5 JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5 JP 2021519849 A JP2021519849 A JP 2021519849A JP 2021519849 A JP2021519849 A JP 2021519849A JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antibody
- use according
- fused
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18199879.0A EP3636284A1 (en) | 2018-10-11 | 2018-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| EP18199879.0 | 2018-10-11 | ||
| PCT/EP2019/077644 WO2020074724A1 (en) | 2018-10-11 | 2019-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512672A JP2022512672A (ja) | 2022-02-07 |
| JP2022512672A5 true JP2022512672A5 (https=) | 2022-10-21 |
| JP7607556B2 JP7607556B2 (ja) | 2024-12-27 |
Family
ID=63833918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519849A Active JP7607556B2 (ja) | 2018-10-11 | 2019-10-11 | アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210379194A1 (https=) |
| EP (2) | EP3636284A1 (https=) |
| JP (1) | JP7607556B2 (https=) |
| KR (1) | KR20210075085A (https=) |
| CN (1) | CN112805037A (https=) |
| AU (1) | AU2019358518A1 (https=) |
| BR (1) | BR112021006269A2 (https=) |
| CA (1) | CA3112848A1 (https=) |
| EA (1) | EA202190653A1 (https=) |
| MX (1) | MX2021003136A (https=) |
| PH (1) | PH12021550750A1 (https=) |
| WO (1) | WO2020074724A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| EP4523704A1 (en) | 2022-05-12 | 2025-03-19 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Camptothecin derivative and ligand-drug conjugate |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| WO2016102679A1 (en) | 2014-12-23 | 2016-06-30 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| EP3256166A1 (en) | 2015-02-09 | 2017-12-20 | NBE Therapeutics AG | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| SG11201803098VA (en) * | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| US20190112385A1 (en) | 2015-10-30 | 2019-04-18 | Nbe-Therapeutics Ag | Anti-mesothelin antibodies |
| SG11201806121PA (en) * | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror2 antibody compositions and related methods |
| UA125718C2 (uk) * | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| ES3034233T3 (en) * | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| CA3035806A1 (en) * | 2016-09-07 | 2018-03-15 | University Of Canberra | Lysine specific histone demethylase-1 inhibitors and uses therefor |
| WO2018103739A1 (zh) * | 2016-12-09 | 2018-06-14 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、制备方法、中间体、药物组合物及应用 |
| EP3641831B1 (en) * | 2017-06-20 | 2024-11-06 | Sorrento Therapeutics, Inc. | Cd38 antibody drug conjugate |
| US20210139579A1 (en) * | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| US11447546B2 (en) | 2017-07-20 | 2022-09-20 | Nbe-Therapeutics Ag | Human antibodies binding to ROR2 |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
-
2018
- 2018-10-11 EP EP18199879.0A patent/EP3636284A1/en not_active Withdrawn
-
2019
- 2019-10-11 JP JP2021519849A patent/JP7607556B2/ja active Active
- 2019-10-11 US US17/283,924 patent/US20210379194A1/en active Pending
- 2019-10-11 AU AU2019358518A patent/AU2019358518A1/en active Pending
- 2019-10-11 EP EP19783544.0A patent/EP3863681A1/en active Pending
- 2019-10-11 CA CA3112848A patent/CA3112848A1/en active Pending
- 2019-10-11 MX MX2021003136A patent/MX2021003136A/es unknown
- 2019-10-11 EA EA202190653A patent/EA202190653A1/ru unknown
- 2019-10-11 KR KR1020217010212A patent/KR20210075085A/ko not_active Ceased
- 2019-10-11 CN CN201980066701.6A patent/CN112805037A/zh active Pending
- 2019-10-11 BR BR112021006269-6A patent/BR112021006269A2/pt unknown
- 2019-10-11 WO PCT/EP2019/077644 patent/WO2020074724A1/en not_active Ceased
-
2021
- 2021-04-05 PH PH12021550750A patent/PH12021550750A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512672A5 (https=) | ||
| JP2025163055A5 (https=) | ||
| JP2022177090A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2022101693A5 (https=) | ||
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| JP2019531084A5 (https=) | ||
| JP2017531028A5 (https=) | ||
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2023549537A5 (https=) | ||
| JP2020534830A5 (https=) | ||
| JP2023539501A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2020521478A5 (https=) | ||
| JP2021508707A5 (https=) | ||
| JP2021513848A5 (https=) | ||
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2020534012A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2005528914A5 (https=) |